Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications
Shakila Meshkat, Manish K. Jha, Venkat Bhat
FOCUS: The Journal of Lifelong Learning in Psychiatry April 1, 2026 DOI: 10.1176/appi.focus.20250043 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Randomized Peer reviewed |
|---|---|
| Intervention | Psilocybin |
| Topics | Psilocybin |
| Keywords | Depression economics Schizophrenia object-oriented programming Medline Hallucinogen |
| Key findings | Psilocybin shows rapid but variable reductions in depressive symptoms and preliminary benefits for anxiety and substance use, but evidence is limited by small samples and short follow-up. |
Abstract
Psilocybin, a serotonergic psychedelic, has gained attention as a potential treatment for various psychiatric conditions. In this review, the authors summarize current clinical evidence related to psilocybin’s efficacy, safety, and mechanisms of action across psychiatric disorders. Findings from early-phase and small-scale clinical trials suggest rapid but variable reductions in depressive symptoms, with some studies reporting sustained effects. Psilocybin has also shown preliminary benefits in alleviating anxiety related to life-threatening illness and in reducing substance use, including alcohol and tobacco dependence. Emerging but limited evidence supports possible therapeutic effects in the treatment of obsessive-compulsive disorder, body dysmorphic disorder, anorexia nervosa, and posttraumatic stress disorder. Reported adverse events, such as headache, nausea, and short-lived anxiety, are typically transient and mild; however, notable adverse reactions have occurred in larger randomized trials. Mechanistically, psilocybin may act by modulating limbic-prefrontal circuits, promoting synaptic plasticity, and enhancing emotional and cognitive flexibility, in particular when administered alongside structured psychotherapeutic support. Although the existing data are encouraging, the evidence base remains limited by small sample sizes, highly selective populations, and short follow-up durations. Larger, rigorously designed trials are required to confirm efficacy, establish long-term safety, and refine therapeutic protocols. Overall, psilocybin represents a promising but still experimental intervention that warrants further systematic investigation under controlled conditions.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |
Citations in the library
Cites 62
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 57 more in the library